(NASDAQ: CPRX) Catalyst Pharmaceuticals's forecast annual revenue growth rate of 9.04% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 112.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23%.
Catalyst Pharmaceuticals's revenue in 2026 is $578,196,000.On average, 10 Wall Street analysts forecast CPRX's revenue for 2026 to be $77,669,566,469, with the lowest CPRX revenue forecast at $71,732,898,177, and the highest CPRX revenue forecast at $81,779,756,690. On average, 8 Wall Street analysts forecast CPRX's revenue for 2027 to be $83,516,508,719, with the lowest CPRX revenue forecast at $76,693,642,116, and the highest CPRX revenue forecast at $92,818,518,167.
In 2028, CPRX is forecast to generate $92,891,036,475 in revenue, with the lowest revenue forecast at $84,733,341,350 and the highest revenue forecast at $108,370,622,494.